ALLMedicine™ Hidradenitis Suppurativa Center

May 18th, 2022 - A woman in her 30s presented to the dermatology clinic with widespread, pruritic, red papules and plaques involving the ears, trunk and extremities. The rash developed a few days after receiving her second injection of secukinumab, which was initi...

May 12th, 2022 - Inflammatory markers and leukocyte profiles have not been longitudinally evaluated as objective signs of hidradenitis suppurativa (HS) severity. We sought to assess C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), interleukin-6 (IL-...

May 12th, 2022 - Hidradenitis suppurativa (HS) is a chronic skin disease of unclear etiology that affects 1 percent (%) to 4% of the general population. JNJ-77474462 (bermekimab) is a recombinant human immunoglobulin G1 kappa (IgG1k) monoclonal antibody (mAb) that...

May 10th, 2022 - Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum.|2022|Scheel CH,Rached NA,Gambichler T,|

May 9th, 2022 - The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)

Nov 5th, 2020 - Owing to the evolving COVID-19 pandemic and emerging data regarding immunosuppressant therapies for inflammatory cutaneous diseases, dermatologists are being encouraged to reevaluate their patients' treatment regimens to minimize any potential ris...

May 12th, 2022 - Hidradenitis suppurativa (HS) is a chronic skin disease of unclear etiology that affects 1 percent (%) to 4% of the general population. JNJ-77474462 (bermekimab) is a recombinant human immunoglobulin G1 kappa (IgG1k) monoclonal antibody (mAb) that...

May 9th, 2022 - The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)

May 5th, 2022 - This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks. This includes an up to 6-week Screening Period, a 16 ...

May 4th, 2022 - This study is open to adults with hidradenitis suppurativa who took part in a previous clinical study of a medicine called spesolimab. Participants who completed treatment can join this study. The purpose of this study is to find out how safe spes...

May 4th, 2022 - Participants will report their pain level daily for 4 weeks. At week 2 and 3, they will get acupuncture in the ears.

Apr 11th, 2022 - BOSTON ― The use of carbon dioxide (CO2) laser excision therapy for hidradenitis suppurativa (HS) is not associated with an increased risk for the development of keloids, new research shows. "With keloids disproportionately affecting Black and oth...

Apr 1st, 2022 - Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by recurrent boils, abscesses, and nodules that can progress to narrow channels that form under the skin. An estimated 1%-4% of the US population has the conditio.

Apr 1st, 2022 - Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by recurrent boils, abscesses, and nodules that can progress to narrow channels that form under the skin. An estimated 1%-4% of the US population has the conditio.

Mar 30th, 2022 - The Diagnosis: Acquired Lymphangioma Circumscriptum A skin biopsy of the plaque on the right labium majus showed a proliferation of well-formed, dilated lymphatic vessels lined by benign-appearing endothelial cells in the papillary dermis (Figure).

Mar 17th, 2022 - Clinic-based surgery for hidradenitis suppurativa (HS) had high patient satisfaction despite frequent recurrences, a retrospective cohort study showed. Patients said they were highly satisfied with results of deroofing surgery and tissue excision ...